Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier

Dow Jones12-09

By Aimee Look

Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease.

The pharmaceutical company said late Monday that it has data showing its Lunsumio drug can be effective alongside lenalidomide for earlier stages of the disease, which builds on its previous observed benefits for later stages of follicular lymphoma.

It comes after Roche's Lunsumio Subcutaneous last month was approved by the European Commission, for relapsed or refractory follicular lymphoma--stages of the disease when initial treatment strategies have not been effective--.

Other forms of Lunsumio have previously been approved by the European Commission and the FDA.

Write to Aimee Look at aimee.look@wsj.com

(END) Dow Jones Newswires

December 09, 2025 01:45 ET (06:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590939032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590939032","market":"hk","top_or_hot":-1,"title":"Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Aimee Look \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease. \n</p>\n<p>\n  The pharmaceutical company said late Monday that it has data showing its Lunsumio drug can be effective alongside lenalidomide for earlier stages of the disease, which builds on its previous observed benefits for later stages of follicular lymphoma. \n</p>\n<p>\n  It comes after Roche's Lunsumio Subcutaneous last month was approved by the European Commission, for relapsed or refractory follicular lymphoma--stages of the disease when initial treatment strategies have not been effective--. \n</p>\n<p>\n  Other forms of Lunsumio have previously been approved by the European Commission and the FDA. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Aimee Look at aimee.look@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2025 01:45 ET (06:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-09 14:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Aimee Look \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease. \n</p>\n<p>\n  The pharmaceutical company said late Monday that it has data showing its Lunsumio drug can be effective alongside lenalidomide for earlier stages of the disease, which builds on its previous observed benefits for later stages of follicular lymphoma. \n</p>\n<p>\n  It comes after Roche's Lunsumio Subcutaneous last month was approved by the European Commission, for relapsed or refractory follicular lymphoma--stages of the disease when initial treatment strategies have not been effective--. \n</p>\n<p>\n  Other forms of Lunsumio have previously been approved by the European Commission and the FDA. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Aimee Look at aimee.look@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 09, 2025 01:45 ET (06:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590939032","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590939032","pubTimestamp":1765262700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease.The pharmaceutical company said late Monday that it has data showing its Lunsumio drug can be effective alongside lenalidomide for earlier stages of the disease, which builds on its previous observed benefits for later stages of follicular lymphoma.It comes after Roche's Lunsumio Subcutaneous last month was approved by the European Commission, for relapsed or refractory follicular lymphoma--stages of the disease when initial treatment strategies have not been effective--.Other forms of Lunsumio have previously been approved by the European Commission and the FDA.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","RHHBY":"罗氏控股","BK4007":"制药"},"translate_title":"罗氏称淋巴瘤治疗药物Lunsumio可能更早见效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"By Aimee Look \n\n\n \n\n\n  Roche said its Lunsumio drug to combat lymphoma, alongside another medicine, might be effective in earlier treatment lines for forms of the disease. \n\n\n  The pharmaceutical company said late Monday that it has data showing its Lunsumio drug can be effective alongside lenalidomide for earlier stages of the disease, which builds on its previous observed benefits for later stages of follicular lymphoma. \n\n\n  It comes after Roche's Lunsumio Subcutaneous last month was approved by the European Commission, for relapsed or refractory follicular lymphoma--stages of the disease when initial treatment strategies have not been effective--. \n\n\n  Other forms of Lunsumio have previously been approved by the European Commission and the FDA. \n\n\n \n\n\n  Write to Aimee Look at aimee.look@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 01:45 ET (06:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590939032","isCrawlerRequest":true}